Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1025)	1/13/2004 10:01:06 PM
From: Greg Rich	Respond to of 1139

Thanks for posting Icebrg. I am a new ICOS investor and am surprised by the lack of activity on this board given the exciting developments at the company (not to mention the bright future). Keep up the good work. Thanks, greg

To: Icebrg who wrote (1025)	1/14/2004 6:15:36 AM
From: Icebrg	Read Replies (1) \| Respond to of 1139

Icos chief stirs up interest in Cialis at investor event By Luke Timmerman Seattle Times business reporter SAN FRANCISCO — Icos Chief Executive Paul Clark keeps hearing the same questions: When are Cialis ads going to hit TV? How fast are prescriptions coming in for the impotence drug? How much of the market is it taking from Viagra? Clark tried yesterday to keep expectations under control while he whipped up enthusiasm for Cialis at the JP Morgan Healthcare Conference, the biotech industry's biggest annual investor event. Clark told investors that Icos and Eli Lilly sales reps were calling doctors to pitch the drug the day after it won approval from the Food and Drug Administration in November, and the drug was shipped to 80 percent of U.S. pharmacies within two weeks. The consumer-ad campaign isn't ready for prime time, but Clark said the Bothell company hopes the FDA will approve the ads to run in the first quarter. And when they arrive, he said, the ads will have bite because, unlike those for rival Levitra, the Cialis ads will most likely describe what the drug is for, including information on benefits and side effects. "They will (emphasize) to men and women, the freedom to choose the moment for intimacy that is right for them," Clark said. But Clark tried to discourage investors from making quick judgments on U.S. sales because the drug just became available during the holiday season. Early sales data will be skewed by pharmacy stocking and won't be a good barometer of patient demand, Clark said. Clark also outlined Icos' other products in development, like RTX, an experimental treatment for frequent and painful urination, and IC485, which recently started a midstage clinical trial in emphysema and chronic bronchitis. Icos' pipeline, which less than two years ago had eight drug candidates, has been trimmed to four. The company is looking to buy partial rights to drugs from another company, Clark said. seattletimes.nwsource.com